Clinical trials are expected to run faster and with less patients if possible. There are significant savings to be had if you can identify patients early for screen failures. Adaptive trials can reduce dropouts and can save time and money for all. During washout phase, you will now have the ability to watch out for "at risk" clinical values. Carematix has served major Pharma in over 20 multi-center studies and 14 countries across the globe for collecting various biometric values.
Self reported data in clinical diaries has been shown to be fraught with errors - over 50%. More accurate records will provide better outcomes. Carematix can even help improve outcomes using its patent pending processes. Real-time data from patients at home helps improve patient compliance and also provides a window into patient behavior between visits. This can affect labeling, outcomes, and marketing programs.
Patient Support and REMS Programs
Payors are reviewing increasing costs of pharmaceuticals in light of outcomes and placement on formularies. A number of payors are seeking performance guarantees. Carematix has patent-pending processes to improve outcomes and even help make the drug more effective. Adherence programs can now be customized to patient behavior. Real data can be used to build REMS programs. Talk to us to learn more.
Carematix can provide you cutting edge ePRO services. We are driving change by focusing on objective Data. We all know subjective patient reported data is unreliable. When possible, objective data is collected directly from home, avoiding transcription errors, patient compensation and outright untrue data. This helps you collect real data on real patients in real-time from their home to enable you to develop drugs quickly, cost effectively and safely.
Carematix has served major Pharma in over 20 multi-center studies and 14 countries across the globe for collecting various biometric values. It is modular in design and can be customized as per study requirements. The solution is adapted to the clinical protocol. Depending on country and program, we use phone lines, broadband or cellular technologies to acquire the data. All data is validated and available for review live on a web portal. At the end of the study, data is transferred as per defined Data Transfer Specification.
Another area that is generating a great deal of interest is “pervasive healthcare,” the use of remote devices to monitor patients on a real- time basis. This will allow the industry to test new medicines outside a clinical setting. Among these are .. wireless blood pressure, glucometer, and weight scales, (Carematix Wellness products), home- based electronic peakflow meters for asthma management .., continuous real-time glucose readings, and several other novel devices, which should enable Novartis to define new approaches to trial design, conduct, safety monitoring, and over- all quality improvements.